research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Neuroscience is the scientific study of the nervous system (the brain, spinal cord, and peripheral nervous system), its functions, and its disorders. It is a multidisciplinary science that combines physiology, anatomy, molecular biology, developmental biology, cytology, psychology, physics, computer science, chemistry, medicine, statistics, and mathematical modeling to understand the fundamental and emergent properties of neurons, glia, and neural circuits. The understanding of the biological basis of learning, memory, behavior, perception, and consciousness has been described by Eric Kandel as the "epic challenge" of the biological sciences. The scope of neuroscience has broadened over time to include different approaches used to study the nervous system at different scales. The techniques used by neuroscientists have expanded enormously, from molecular and cellular studies of individual neurons to imaging of sensory, motor, and cognitive tasks in the brain.
A number of experiments have found that decay rates of other modes of artificial and naturally occurring radioisotopes are, to a high degree of precision, unaffected by external conditions such as temperature, pressure, the chemical environment, and electric, magnetic, or gravitational fields. Comparison of laboratory experiments over the last century, studies of the Oklo natural nuclear reactor (which exemplified the effects of thermal neutrons on nuclear decay), and astrophysical observations of the luminosity decays of distant supernovae (which occurred far away so the light has taken a great deal of time to reach us), for example, strongly indicate that unperturbed decay rates have been constant (at least to within the limitations of small experimental errors) as a function of time as well. Recent results suggest the possibility that decay rates might have a weak dependence on environmental factors. It has been suggested that measurements of decay rates of silicon-32, manganese-54, and radium-226 exhibit small seasonal variations (of the order of 0.1%). However, such measurements are highly susceptible to systematic errors, and a subsequent paper has found no evidence for such correlations in seven other isotopes (22Na, 44Ti, 108Ag, 121Sn, 133Ba, 241Am, 238Pu), and sets upper limits on the size of any such effects.
== Research == Oxyntomodulin could be a potential candidate for treating obesity because of its ability to suppress appetite. In a 4 week study, healthy overweight and obese volunteers were given either saline or oxyntomodulin injections. Their body weight, energy intake, and the levels of adipose hormones were taken prior to the treatment. The volunteers maintained their usual diets and daily activities and self-administered the injections three times daily, 30 minutes before their meals. In the course of 4 weeks, volunteers treated with oxyntomodulin injections had an average weight loss of 2.3±0.4 kg compared to those treated with saline who had an average of 0.5±0.5 kg, indicating oxyntomodulin was successful in weight loss.
Sources: en.wikipedia.org
Specifically, the complex of TAP, tapasin, MHS Class 1, ERp57, and calreticulin is called the peptide-loading complex (PLC). Peptides are loaded to MHC-I peptide binding groove between two alpha helices at the bottom of the α1 and α2 domains of the MHC class I molecule. After releasing from tapasin, peptide-MHC-I complexes (pMHC-I) exit the ER and are transported to the cell surface by exocytic vesicles. Naïve anti-viral T cells (CD8+) cannot directly eliminate transformed or infected cells. They have to be activated by the pMHC-I complexes of antigen-presenting cells (APCs). Here, antigen can be presented directly (as described above) or indirectly (cross-presentation) from virus-infected and non-infected cells. After the interaction between pMHC-I and TCR, in presence of co-stimulatory signals and/or cytokines, T cells are activated, migrate to the peripheral tissues and kill the target cells (infected or damaged cells) by inducing cytotoxicity. Cross-presentation is a special case in which MHC-I molecules are able to present extracellular antigens, usually displayed only by MHC-II molecules. This ability appears in several APCs, mainly plasmacytoid dendritic cells in tissues that stimulate CD8+ T cells directly. This process is essential when APCs are not directly infected, triggering local antiviral and anti-tumor immune responses immediately without trafficking the APCs in the local lymph nodes.
The elaboration of a method for the reduction of aromatic rings to the corresponding dihydrobenzenes under controlled conditions by A. J. Birch opened a convenient route to compounds related to the putative 19-norprogesterone. This reaction, now known as the Birch reduction, is typified by the treatment of the monomethyl ether of estradiol (1) with a solution of lithium metal in liquid ammonia in the presence of alcohol as a proton source. Initial reaction constituents of 1,4-dimetalation of the most electron deficient positions of the aromatic ring–in the case of an estrogen, the 1 and 4-positions. Rxn of the intermediate with the proton source leads to a dihydrobenzene; a special virtue of this sequence in steroids is the fact that the double bond at 2 is in effect becomes an enol ether moiety. Treatment of this product, 1,4-Dihydroestradiol 3-methyl ether [1091-93-6] (2), with weak acid, e.g. oxalic acid, leads to the hydrolysis of the enol ether, producing β,γ-unconjugated ketone Prenortestosterone [1089-78-7] (3). Hydrolysis under more strenuous conditions (mineral acids) results in migration/conjugation of the olefin to yield nandrolone (4). The Prenortestosterone [1089-78-7] is also of interest to us because it has use in the synthesis of Dienolone. Birch reduction of estrone methyl ether will work. Back-oxidation of the 17beta-hydroxy group will give Bolandione (cmp 14). Reduction of the 3-keto group in nandrolone (lithium aluminium hydride was given in patent) will give bolandiol.
=== Urinary preparations === Purified urinary FSH (75 IU FSH and ≤ 2 IU of LH) Generic urofollitropin for injection, purified. Brands Bravelle, U.S., (≤ 2 IU LH) Metrodin, U.S. and Canada, (≤ 1 IU LH) Fertinorm Hp, (Canada) Highly purified urinary FSH (75 IU FSH and ≤ 0.1 IU LH/1000 IU FSH) Generic urofollitropin for injection, (highly) purified. Brands Fertinex (≤ 0.1 IU LH/1000 IU FSH)
horizontal gene transfer (HGT) Also lateral gene transfer (LGT). Any process by which genetic material is transferred between unicellular and/or multicellular organisms other than by vertical transmission from parent to offspring, e.g. bacterial conjugation.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.